Please assess the completion status of the following clinical trial:

Trial Title: A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naive~* Chronic, compensated HCV GT1 infection~* Absence (no medical history or physical findings) of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease, or cirrhosis~* No evidence of cirrhosis or hepatocellular carcinoma by biopsy or noninvasive testing (e.g. FibroScan and/or FibroTest)~* Must agree to use two acceptable methods of birth control from at least 2 weeks prior to first dose and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations~Exclusion Criteria:~* Non-GT1 HCV infection, including a mixed GT infection (with a non-GT1) or a non-typeable genotype.~* Documented to be Human Immunodeficiency Virus (HIV) positive or co-infected with hepatitis B virus~* Hepatocellular carcinoma (HCC) or under evaluation for HCC~* Participating in or has participated in a study with an investigational compound or device within 30 days of signing informed consent~* Diabetic and/or hypertensive with clinically significant ocular examination findings~* Current or history of central nervous system trauma, seizure disorder, stroke or transient ischemic attack~* Chronic pulmonary disease~* Current or history of any clinically significant cardiac abnormalities/dysfunction~* Active clinical gout within the last year~* History of gastric surgery or history of malabsorption disorders~* Active or suspected malignancy, or a history of malignancy, within the last 5 years (except adequately treated carcinoma in situ and basal cell carcinoma of the skin)~* Pregnant, lactating, expecting to conceive or donate eggs, or male participant planning to impregnate or provide sperm donation or with a female partner who is pregnant~* Current moderate or severe depression or history of depression associated with hospitalization, electroconvulsive therapy, or severe disruption of daily functions, or suicidal or homicidal ideation and/or attempt, or history of severe psychiatric disorders~* Evidence or history of chronic hepatitis not caused by HCV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Grazoprevir 25 mg + PEG-IFN + RBV (Type: EXPERIMENTAL): After a maximum of a 45 day screening window, randomized participants receive 25 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by Response Guided Therapy (RGT). Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their Hepatitis C virus ribonucleic acid (HCV RNA) level at Treatment Week (TW) 4.
- Grazoprevir 50 mg + PEG-IFN + RBV (Type: EXPERIMENTAL): After a maximum of a 45 day screening window, randomized participants receive 50 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
- Grazoprevir 100 mg + PEG-IFN + RBV (Type: EXPERIMENTAL): After a maximum of a 45 day screening window, randomized participants receive 100 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).